Dr. Soloway attended Northwestern University. He received his MD from Case Western Reserve University in Cleveland, Ohio, and subsequently his urology training at University Hospitals of Cleveland. He spent two years as a clinical associate at the National Cancer Institute, NIH, where he developed an animal model for bladder cancer which is still being used to study this cancer. He was awarded the Gold Cystoscope Award by the American Urologic Association in 1984. Dr. Soloway was appointed to his present position as Chairman of the Department of Urology at the University of Miami School of Medicine in 1991, following 16 years as Chief of Urologic Oncology at the University of Tennessee-Memphis Center for the Health Sciences.

Dr. Soloway has authored over 300 articles on prostate, bladder and kidney cancer. He has been a featured speaker at numerous national and international meetings. He has popularized the case discussion format as a teaching method in an effort to assimilate scientific data into the clinic setting.Some of Dr. Soloway’s major contributions include the role of periprostatic nerve block for prostate biopsy, technical modifications in prostatectomy for prostate cancer, rationale for intravesical chemotherapy for bladder cancer and a grading scale for bone scans in prostate cancer. Dr. Soloway was one of the first to identify the efficacy of cisplatin for urothelial cancer and for the additive effect of cisplatin with radiation. Dr. Soloway chaired the International Consultation on Bladder Cancer which was sponsored by the Sociéte Internationale de Urologie (SIU). Over 100 urologists, medical oncologists, pathologists, and radiation oncologists came together to provide guidelines on bladder cancer.

Selected Publications:

• Presentation and outcome following radical cystectomy in Hispanics with bladder cancer


• Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey


• Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study


• Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter


• Small Cell Carcinoma of the Bladder


• Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy


• Non-Transitional Cell Bladder Carcinomas


• Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder


• Intraoperative cell salvage during radical cystectomy does not affect long-term survival


• Is Intravesical Chemotherapy for Superficial Bladder Cancer Still Justified?


• Does body mass index affect outcome after reconstruction of orthotopic neobladder?


• Complications of intravesical therapy for urothelial cancer of the bladder


• Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation


• The diagnosis and staging of bladder cancer: from RBCs to TURs


• Surveillance for recurrent bladder cancer using a point-of-care proteomic assay


• Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder


• Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder?


• Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting


• Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Guérin-induced bladder contractures


• Optimal management of the T1G3 bladder cancer


• Detection of bladder cancer using a point-of-care proteomic assay


• Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring


• Upper tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: incidence and risk factors


• Current bladder cancer tests: unnecessary or beneficial?


• Expectant management of small, recurrent, noninvasive papillary bladder tumors


• Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests


• Current bladder tumor tests: does their projected utility fulfill clinical necessity?


• De novo muscle invasive bladder cancer: is there a change in trend?


• The value of upper tract cytology after transurethral resection of bladder tumor in patients with bladder transitional cell cancer

Multimedia Presentations:

• Diagnosing Bladder Cancer (CME)

In Conferences:

• Underlying Role of Intravesical Therapy of "Superficial" TCCA with Animal Model


• Bladder Cancer I: Non-muscle Invasive Bladder Cancer - SIU Guidelines


• High Grade T1 Bladder Cancer: Who Should Undergo Early Cystectomy?


• Society of Urologic Oncology Meeting: Cystectomy vs. BCG for T1